
price data provid thomson reuter
number may add due round
initi neutral biotech bellweth find way
initi coverag neutral rate price target
compani look move beyond recent aducanumab/alzheim diseas
ad setback see crossroad pipelin hold
numer early-stag asset like make near-term top-lin impact
acknowledg need novel therapeut remain stronger
ever howev pipelin situat complic on-going
inter part review ipr tecfidera patent could open door
gener competit sooner anticip bottom line await clariti
multipl front get construct
gone forgotten aducanumab setback creat challeng earli
aducanumab pivot termin caught biotech world surpris
think mark start away anti-amyloid-bas therapi
open sector toward novel ad target good thing
current pipelin continu hold five differ ad program eisai
collabor remain place surpris see
move differ direct
enough alreadi tecfidera ipr proceed creat
overhang normal circumst rebuild late-stag pipelin
pose daunt task compani layer ad challeng
potenti earli exclus loss tecfidera largest sourc product
revenu even complic report us tecfidera
account total product revenu present patent provid
us exclus howev fall ipr proceed
final orang book-list patent expir octob open
door potenti gener competit shortli thereaft gener
entri fair valu fall creat potenti risk expect
februari decis like chanc prevail ipr
proceed littl upsid estim exclus remain
intact bottom line littl way altern catalyst see ipr
litig keep overhang share
amidst near-term challeng initi neutral vumer head-to-head data
versu tecfidera help demonstr whether gi toler
benefit manifest vumer earli data suggest declin gi-
relat discontinu encourag thu far one question remain
discontinu due advers event flush impact
real-world util bottom line opportun could add
share valuat data critic evalu investor like
remain focus tecfidera ipr situat limit near-term
catalyst help share work higher thu fair valu estim
initi coverag neutral rate
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
inc commercial-stag biotechnolog compani focus develop novel therapeut
neurolog neurodegen condit current product portfolio encompass nine approv
product three partner therapi pipelin span agent variou develop stage follow
termin high-profil asset aducanumab alzheim diseas advanc effort lie
vumer diroximel fumar tecfidera prodrug develop collabor partner vumer
final stage fda review decis anticip see one premier
leader space current state pipelin present limit near-term opportun investor
commerci environ like remain challeng thu hold cautiou outlook share
await pipelin develop
loss tecfidera exclus caus
sever commerci eros
maintain defens posit
vumer help maintain
acceler growth
ms
unchalleng gene therapi
potenti regulatori approv vumer
target deriv multipl
ep estim discount back
discount peer consensu ep due
boston-headquart commercial-stag
biopharma focus develop novel treatment
neurolog neurodegen disord
given remain largest top-lin contributor
tecfidera repres key valu driver current
follow aducanumab
readout debat pipelin activ commerci
mix
creat bluematrix
tabl content
aducanumab what
aducanumab alter pipelin path forward
pipelin review plenti shot chang focu debat
next tecfidera vumer draw closer finish line
set stage walk vumer vs tecfidera
vumer date toler data seen far
put tecfidera gi discontinu context
success vumer look like
pursu ipr key tecfidera patent
feel like first time tecfidera patent stranger ipr
look ahead key mileston ipr proceed
settlement option look ipr statist
valuat deep dive top bottom
zero biotech sector valuat
tabl figur
anticip clinic readout
incid gi advers event time
ipr timelin written decis
summari conclus initi coverag inc neutral rate
price target neurology-focus powerhous continu hold broad foot
multipl sclerosi ms space recent exit aducanumab leav pipelin
limit late-stag opportun make situat complic recent institut
ipr challeng tecfidera patent creat anoth overhang investor
specter gener entri loom although remain impress breadth
overal pipelin share trade see balanc risk/reward given
near-term uncertainti initi neutral target
aducanumab address pipelin
earli termin aducanumab develop campaign alzheim diseas ad
significantli dampen interest pursu amyloid-beta target therapeut candid
move setback compani remain commit ad drug develop
current pipelin program target ad press issu investor time
crunch littl way late-stag candid pivot readout like manifest
think pressur pursu candid remain strong creat
urgenc manag find addit novel late-stag target supplement effort
limit near-term late-stag readout horizon us tecfidera sale repres
compani revenu base investor focus on-going inter part review
ipr tecfidera orang book-list method use patent us potenti
outcom proceed us patent trial appeal board ptab side
challeng strike valid patent claim written decis
februari could face potenti gener entri us pend
appeal previous prevail separ ipr challeng patent
think potenti withstand current challeng step back
upside/downsid analysi indic downsid risk gener entri manifest earli
challeng base busi near-term upsid driver limit
impress biib commit tackl broad rang neurolog condit
signific unmet need absenc meaning late-stag pipelin readout near-
term pose challeng amidst tecfidera ip challeng bear/base/bul case scenario
analysi suggest balanc risk/reward share could make us
construct share clariti tecfidera exclus runway acquisit addit
late-stage/commerci opportun two logic factor could caus us revisit
thesi thu initi coverag neutral rate target
current market suit product tecfidera dimethyl fumar avonex plegridi tysabri fampyra spinraza benepali imraldi flixabi fumaderm
addit variou collabor collect royalti agent includ ocrevu rituxan/gazyva figur illustr current
develop pipelin product portfolio includ partner asset hold econom roch ocrevu note partner alkerm
current file review vumer diroximel fumar prodrug relat tecfidera
describ detail herein deriv price target share use
compar multipl approach appli multipl non-gaap ep estim
discount back per year given compani stage develop earn
histori feel appropri approach compani addit valuat
methodolog use deriv altern fair valu estim compar
aducanumab what
aducanumab alter pipelin path forward
march announc follow interim analysi phase engag
emerg studi would discontinu decis termin studi mild cognit
impairment/mild alzheim diseas ad patient occur futil analysi determin
studi unlik meet primari endpoint aducanumab repres signific
valu driver investor disappoint result evidenc
declin share result announc
howev aducanumab also repres one biib advanc late-stag asset
remain broad span differ program diseas indic
includ potenti gene therapi effort soon inherit recent announc nightstar
therapeut acquisit overal believ loss aducanumab necessarili
increas urgenc expand pipelin discuss contend
need address number late-stag asset oppos continu broaden
pipelin review plenti shot chang focu debat
attempt review recent histori biib pipelin better understand
chang head compar pipelin snapshot come away two
main conclus first see littl chang need late-stag asset remain
unchang continu need view second nearli quarter biib
program focus ad pipelin encompass ad/ms/pain probabl
success like remain challeng
figur summar pipelin two year ago time
point held eleven market products/royalti program along develop
program pipelin program demarc red figur longer
develop present time repres roughli one-third program
figur provid visual snapshot current pipelin biib total number market product drop eleven eight
compani spun hemophilia franchis zinbryta discontinu off-set collect royalti ocrevu sale
develop pipelin expand total program even elimin aducanumab program circl next program indic
whether program new advanc sinc april green chang note analysi incorpor current
program statu whether program advanc addit incorpor addit program integr pend nightstar
overal littl chang number advanc program sinc number phase phase asset increas
acknowledg acceler review condens develop plan may option advanc program rapidli howev mani indic
ad challeng see much time could reduc compar prior effort
figur attempt provid differ visual current pipelin segreg program accord disease/ind stage
develop file phase phase phase red bar denot total number program disease/ind approxim
pipelin concentr ad ms pain see figur
mani program develop figur illustr clinic readout
anticip read prior beyond near-term head-to-head data vumer
expect major readout repres earlier-stag
data point stock perspect see limit impact major
readout given develop stage tecfidera patent challeng occur
anticip clinic readout
note mild-to-moder acut ischem stroke patient present within hour last known normal
drug-resist focal epilepsi data file
next tecfidera vumer draw closer finish line
novemb secur collabor agreement
known vumer aka diroximel fumar monomethyl fumar prodrug
metabol activ form tecfidera thu far file new drug
applic nda leverag approv pathway use tecfidera
refer drug short basi applic reli complet
bioequival bridg studi single-arm long-term safeti studi evolve-m file
applic await pdufa drug
one addit studi still on-going repres import data point establish
differenti versu tecfidera studi directli compar tecfidera
vumer head-to-head studi five week evalu differ rate gi
symptom describ detail emphasi gi toler particularli
relev frequent caus discontinu among tecfidera user word
vumer share similar efficaci tecfidera improv toler would seem
hold differenti studi top-lin data expect arriv
limit late-stag pipelin readout near term tecfidera face potenti
intellectu properti ip challeng mylan ipr see import event
set stage walk vumer vs tecfidera
figur illustr trial design evalu potenti
toler differ vumer aka tecfidera dmf
screen lead-in period subject random differ treatment arm
primari endpoint focus number day gi event use individu
gastrointestin symptom impact scale igisi scale evalu five
addit secondari efficaci endpoint also incorpor manag note
emphasi encompass multipl aspect gi toler includ thing frequenc
event durat sever
vumer date toler data seen far
prior data vumer studi demonstr
low rate
discontinu due gastrointestin gi event although gi advers event occur
patient month previou data present ectrim
meet show seriou gi throughout first month studi incid
diarrhea see figur
recent present data meet demonstr gi
discontinu rate remain treatment period nearli two year week
overal treatment discontinu see figur howev note would
fall report rate disease-modifi treatment ms space vari
notabl flush rate appear remain similar across vumer
intact toler seemingli offer
thu efficaci appear remain
improv tecfidera term gi discontinu key remain question
might vumer stack versu tecfidera direct comparison end attempt
explor upcom readout directli evalu vumer tecfidera
effect gi advers event
put tecfidera gi discontinu context
overal discontinu rate appear lower vumer tecfidera incid
rate appear differ two drug one recent public detail
real-world rate advers retrospect analysi dmf-treat tecfidera
patient research found patient discontinu treatment within one year
first year approxim patient report least one gi event dmf treatment
interestingli report gi event occur first five week treatment
yet discontinu treatment due gi event figur illustr frequenc
event week start treatment percent event lead
discontinu see figur
incid gi advers event time
site evalu min analysi encompass global region discontinu rate
due gi event greater us compar area europ
could repres import distinct cross-trial comparison mani limit
howev overal note discontinu rate vumer first month
treatment appear stack favor rel real-world
discontinu rate tecfidera first five week treatment
success vumer look like
although differenti versu tecfidera import vumer gain meaning
traction ms space rel limit term degre magnitud
improv seek achiev rel tecfidera consid major
gi-rel tecfidera discontinu manifest first week treatment
studi focus time frame studi incorpor patient-report outcom
tie frequenc durat sever event somewhat challeng ascertain
data may compar
gi incid rate vumer latest data cut appear meaning
differ observ tecfidera
thu anticip frequenc
measur like similar term durat sever event given
reduct discontinu vumer seen date rel tecfidera assum
translat improv vumer
present incorpor vumer estim await head-to-head data
better understand drug may fit commerci landscap one hand
appear promis decreas gi-rel discontinu avail data
howev incid event appear unchang moreov incid advers
event flush appear differ meaning vumer tecfidera
think likelihood approv strong bigger question drug
perceiv patient physician end await forthcom data better
understand toler profil comparison
pursu ipr key tecfidera patent
juli sought inter part review ipr biib tecfidera patent us
us patent trial appeal board ptab ipr challeng legal proceed
challeng valid patent claim repres condens strategi
tradit patent challeng case challeng base premis
patent invalid due obvious
figur illustr step ipr process ptab make decis ipr
institut month file final written decis board arriv later
month februari ptab institut ipr patent translat
ipr timelin written decis
patent repres critic exclus barrier prove success
ipr challeng tecfidera patent remain patent offer limit
protect within us tabl illustr five orang book-list patent
tecfidera patent recent expir patent expir
octob patent remain effect june patent
hold expiri option maintain tecfidera exclus
patent valid success challeng
feel like first time tecfidera patent stranger ipr
stranger ipr process specif alreadi face review relat
patent ptab rule uphold claim specifi patent ipr
proceed initi kyle bass coalit afford drug similar
current proceed ipr attempt challeng patent ground
patent describ method treatment dose tecfidera ms patient
particular dose import relat prior tecfidera studi phase
clinic trial dose demonstr efficaci dose fail show signific
benefit subsequ phase studi dose found efficaci
behav like dose dose argu past
drug demonstr dose-depend result phase studi end result
efficaci dose unexpect given closer dose word
increas drug small amount gave larg improv efficaci nonobvi
argu although coalit argu expect board found
magnitud benefit dose expect thu prevail patent
claim upheld
current ipr proceed argu dose efficaci obviou
result what new argument introduct addit evid clinic trial
evalu dose two separ dose period conduct
argu new evid suggest dose efficaci therefor
subsequ result would deem obviou remain debat point
proceed whether new evid actual depict dose efficaci
overal inspect new document come away struggl see signific
evid support view dose would clearli efficaci
given fact board alreadi review valid claim earlier ipr
proceed think like good posit demonstr non-obvi
dose maintain valid patent claim
look ahead key mileston ipr proceed
base current stipul schedul order time ptab final written decis
project februari tabl illustr time addit mileston
case prevail could seek appeal rule ptab would add
month litig proceed current statist publish ptab indic appeal success
rate rel modest rule revers appeal approxim
ptab rule affirm either full part thu current orang book-list
patent expir could creat open gener competitor us
settlement option look ipr statist
ipr process differ post grant review patent limit ground
challeng ptab also requir complet ipr within month institut
one distinct area settlement parti statist report
ptab indic ipr result settlement institut arent rate
higher one reason may settlement may necessarili result termin
ipr word ptab may still issu decis patent valid even parti
settl prior report see suggest earlier process settlement
parti propos like ptab would grant termin
actionplannedoriginaldu respons petit motion repli respons opposit motion sur-repli repli repli sur-repli repli opposit motion exclud evid request oral motion opposit motion exclud request prehear date
request given statist past histori patent think chanc remain
low settlement emerg proceed
stake win ipr proceed high april fda drug
master file dmf repositori list differ activ dmf dimethyl fumar given
size tecfidera us revenu opportun anticip rapid gener entri eros
scenario describ model detail start term put
potenti exclus loss context evalu impact estim use sum-of-
current sum-of-part analysi deriv fair valu biib exist base busi
share current trade import note
analysi assign credit pipelin program tabl illustr four
potenti outcom ipr proceed versu two logic outcom
ipr decis either favor believ greater probabl
success associ biib posit patent claim upheld fair
valu estim would remain intact success invalid patent
would creat opportun us gener entri begin scenario fair
valu drop includ scenario settlement think
probabl settlement low
describ detail current market model ms market ad
space numer pipelin effort underway await proof-of-concept
data assign full credit model major campaign
scenarioprobabilityvaluationbiib prevail patent exclus remain prevail patent remov us revenu settlement patent remov us revenu settlement patent remov us revenu fair
base literatur estim biib current ms product portfolio ms market model focus larg relapsing/remit ms rrm popul
estim group encompass patient us activ treatment yield final popul rrm elig
patient figur illustr current tecfidera market estim figur illustr assumpt us tecfidera estim
multipl sclerosi ms market market -- rrmsestim rrm address market avail market avail assumpt scenario analysisu price increas launchbas case single-digit growth case mid single-digit growth case singl digit declin tecfidera market share base case share eros begin case exclus maintain case exclus expir ms revenu tecfideraestim tecfidera market share per patient per annual price us revenu
present assum low single-digit price increas tecfidera us
potenti eros us begin remain ms franchis product
avonex plegridi tysabri assum stabl slightli decreas market share oral
product continu hold traction
second largest sourc product revenu current deriv biib spinraza
approv treatment spinal muscular atrophi sma base literatur estim
assum roughli sma patient major preval popul
compris type ii type type patient typic short surviv make larg
incid popul roughli case occur per year spinraza
target therapi begin provid surviv benefit type popul could see growth
time
figur illustr current assumpt us sma market potenti
competit agent enter landscap assum spinraza revenu moder
begin see figur
spinal muscular atrophi sma market market -- smaestim sma -- total patient type type ii type estim patient elig type type estim patient start i- type type estim total patient estim total patient load mainten dose per estim total dose per load dose revenu period annual price us revenu
valuat deep dive top bottom
zero biotech sector valuat
tabl summar current valuat metric large-cap mid-cap commerci
stage biotechnolog compani among large-cap note group current trade
mean price-to-earnings rel consensu ep estim p/ metric group trade
mean multipl consensu revenu
note price
compar histor basi figur attempt put tempor context
around current sector-level valuat histor sinc large-cap peer group
trade consensu earn rel typic premium
howev note diverg trend biotech trade
meaning discount see
figur illustr recent trade histori share event impact
share either posit neg overal inflect point coincid data
readout financi result competit updat look ahead near term see
key valu driver stock tecfidera
previous state deriv price target use earn multipl approach
primari valuat methodolog believ repres appropri approach
matur commercial-stag biotech like particularli establish histori
assumpt incorpor base case analysi includ discount rate
termin growth rate incorpor analys regard specif program
incorpor assign full credit exist product portfolio revenu extend
period regulatori exclus instanc addit issu
patent extend runway factor timelin estim pipelin
opportun hold incorpor credit vumer ms current
estim await head-to-head clinic data versu tecfidera better understand
recent agre acquir nightstar therapeut give access
new gene therapi platform deal anticip close await
clariti effort priorit current hold net debt posit
debt total cash
price-to-earnings multipl approach repres primari valuat methodolog use deriv
price target also examin potenti valuat use altern method note
like primari approach altern methodolog also sensit select
discount rate multipl valuat year figur illustr fair valu
shown figur select valuat year p/ analysi
consist primari valuat methodolog addit also adher
discount rate mid-cap large-cap biotech current trade consensu
revenu current multipl discount peer group still premium
share trade believ appropri multipl base current revenu growth
prospect competit landscap
shown figur also deriv potenti fair valu use sum-of-part
dcf methodolog stay consist discount rate use methodolog
assign credit current market product deriv fair valu estim
methodolog yield fair valu estim deviat two
methodolog howev larg assumpt potenti cash flow
pipelin program flow tecfidera compris major valuat
deriv base case price target share also examin potenti
bull bear case scenario better understand current upside/downsid movement
rel share current trade see press downsid scenario one
tecfidera us exclus end period previous discuss could yield
downsid rel share current trade
pipelin success incorpor new asset acquir via busi develop
transact repres logic sourc upsid vumer may repres near-term
driver howev heavili lever toward clinic differenti versu tecfidera
assum product achiev current tecfidera us revenu opportun
could add valuat risk-adjust basi unadjust
beyond pipelin success multipl expans next logic lever move closer mean
price-to-earnings multipl group still discount would yield fair valu
upsid given current setup question surround length tecfidera
exclus addit pipelin readout still manifest see near term driver
would serv catalyst chang bottom line risk/reward appear rel balanc
rel share current trade figur summar scenario
inc boston-bas commercial-stag biopharma focus discov
develop market novel therapi neurolog neurodegen condit
found one origin biotech amass best-in-class portfolio
ms product beyond core compet protein engin broaden
effort assembl broad develop pipelin span differ program
encompass small molecul biolog rna-bas therapi gene therapi
figur illustr current element manag financi guidanc
note guidanc issu prior pend nightstar therapeut acquisit
manag current polici provid semi-annual updat thu anticip next
updat financi result
discoveri
develop market biopharma product member execut team
describ
mr vounatso join promot role ceo prior
join mr vounatso spent year merck hold varieti senior role across
multipl busi line addit experi merck mr vounatso also held
manag posit ciba-geigi mr vounatso obtain hec school
mr capello join serv cfo sinc point time prior
appoint mr capello previous held cfo role compani beacon
health option ortho clinic diagnost boston scientif corpor mr
capello obtain univers vermont harvard busi
michael ehler evp head
dr ehler join current role head prior appoint
dr ehler serv senior leadership role addit industri
experi dr ehler serv professor neurobiolog duke univers medic center
dr ehler obtain bs california institut technolog receiv
ph john hopkin univers
dr sandrock join held numer senior level posit
appoint current role chief medic offic dr sandrock receiv
stanford univers harvard medic school ph harvard
reahl cohan three-year clinic outcom relaps multipl sclerosi patient
treat dimethyl fumar unit state commun health center mult
 miller chan real-world character dimethyl fumarate-rel
gastrointestin event multipl sclerosi manag strategi improv
persist treatment patient outcom neurol ther
tremlett persist adher new oral disease-modifi therapi
longbrak cross salter efficaci toler oral versu inject
disease-modifi therapi multipl sclerosi clinic practic mult scler
target deriv multipl ep estim discount back discount peer
consensu ep due compani matur product portfolio
risk attain price rate
clinic data emerg clinic studi significantli impact share either posit neg direct
regulatori employ acceler strategi gain approv regul may requir addit data could alter
requir approv necessit addit longer studi failur gain product label lack certain featur could
limit abil gain traction market
commerci failur execut commerci inabl meet/exce expect impact share
competit updat competitor may posit neg impact share relev competitor includ compani
novarti roch sanofi lilli teva sandoz competitor like emerg time
generic/biosimilar entri new gener biosimilar agent may put pressur exist market product
limit compani abil realiz increas price
laura chico certifi view express report accur reflect person opinion
directli indirectli receiv compens payment connect specif recommend view contain
report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
may
may
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
